Grifols SA ADR is a drug manufacturers-general business based in the US. Grifols SA ADR shares (GRFS) are listed on the NASDAQ and all prices are listed in US Dollars. Grifols SA ADR employs 23,631 staff and has a trailing 12-month revenue of around $6.5 billion.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $9.40 |
|---|---|
| 52-week range | $5.71 - $10.97 |
| 50-day moving average | $9.91 |
| 200-day moving average | $8.80 |
| Wall St. target price | $13.92 |
| PE ratio | 54.1667 |
| Dividend yield | $0 (7.09%) |
| Earnings per share (TTM) | $0.18 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $9.4 from 2023-09-22
| 1 week (2023-09-15) | -4.95% |
|---|---|
| 1 month (2023-08-24) | -3.39% |
| 3 months (2023-06-23) | 5.26% |
| 6 months (2023-03-24) | 37.23% |
| 1 year (2022-09-23) | 33.71% |
|---|---|
| 2 years (2021-09-24) | -38.52% |
| 3 years (2020-09-24) | 16.0783 |
| 5 years (2018-09-24) | 19.8235 |
Valuing Grifols SA ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Grifols SA ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
| Revenue TTM | $6.5 billion |
|---|---|
| Operating margin TTM | 9.47% |
| Gross profit TTM | $2.2 billion |
| Return on assets TTM | 1.81% |
| Return on equity TTM | 1.24% |
| Profit margin | 0.13% |
| Book value | $4.32 |
| Market Capitalization | $8.2 billion |
TTM: trailing 12 months
We're not expecting Grifols SA ADR to pay a dividend over the next 12 months.
Grifols SA ADR's shares were split on a 2:1 basis on 3 January 2016. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Grifols SA ADR shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Grifols SA ADR shares which in turn could have impacted Grifols SA ADR's share price.
Over the last 12 months, Grifols SA ADR's shares have ranged in value from as little as $5.71 up to $10.965. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Grifols SA ADR's is 0.4572. This would suggest that Grifols SA ADR's shares are less volatile than average (for this exchange).
Grifols, S. A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product. The Diagnostic segment offers transfusion medicine, which includes Procleix Panther systems/Procleix Panther with Automation Ready technology, Automated NAT blood screening systems, assays, software, WADiana/Erytra/Erytra Eflexys analyzers, BLOODchip ID/IDCore/IDHPA/IDRHD/IDCORE/BIDS, and antigens; and clinical and diagnostics products, such as Promonitor and Alpha1D. The Bio Supplies segment provides human biological materials for life sciences research and the development and manufacturing of pharmaceutical and diagnostic products. The Others segment offers healthcare solutions, which provides services and manufactures products, including parenteral solutions, robotics, and software used by hospitals, blood banks, plasma collection centers and other healthcare systems.
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.